会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 11. 发明授权
    • Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
    • 使用(2-咪唑啉-2-基氨基)喹喔啉衍生物的方法
    • US5231096A
    • 1993-07-27
    • US820329
    • 1992-01-13
    • Charles GluchowskiMichael E. GarstJames A. BurkeLarry A. Wheeler
    • Charles GluchowskiMichael E. GarstJames A. BurkeLarry A. Wheeler
    • C07D403/12A61K31/495A61P7/10A61P9/08A61P9/10A61P27/02
    • C07D403/12A61K31/495Y10S514/816
    • A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## ,pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R.sub.2 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R.sub.3 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7- or 8- positions of the quinoxaline nucleus; and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as reduction in peripheral pain, anesthetization of the central nervous system, constriction of one or more blood vessels, reduction in or prevention of at least one effect of ischemia, decongestion of one or more nasal passages, and reduction of at least one effect of an inflammatory disorder.
    • 治疗哺乳动物的方法包括向哺乳动物施用有效量以在哺乳动物中提供选自下列化合物的化合物所需的治疗效果:具有下式的那些化合物:其药学上可接受的酸加成盐及其混合物 其中R 1和R 4独立地选自H和具有1至4个碳原子的烷基; R 2独立地选自H或具有1至4个碳原子的烷基,或者一起是氧代; R 3独立地选自H或具有1至4个碳原子的烷基,或者一起是氧代; 2-咪唑啉-2-基氨基可以在喹喔啉核的5-,6,7或8-位中的任一个中; 并且R5,R6和R7各自位于喹喔啉核的剩余的5-,6-,7-或8-位中的一个中,并且独立地选自Cl,Br,H和具有1至 3个碳原子。 当向哺乳动物施用时,这些化合物提供期望的治疗效果,例如减少周围疼痛,中枢神经系统麻醉,一个或多个血管的收缩,减少或预防至少一种缺血作用,减压 一个或多个鼻通道,以及减少至少一种炎症性疾病的作用。
    • 12. 发明授权
    • Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
    • 使用(2-咪唑啉-2-基氨基)喹喔啉衍生物的方法
    • US06323204B1
    • 2001-11-27
    • US09222844
    • 1998-12-30
    • James A. BurkeMichael E. GarstLarry A. Wheeler
    • James A. BurkeMichael E. GarstLarry A. Wheeler
    • A61K31495
    • A61K31/495A61K31/498
    • A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: and pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R1 and R2 each is selected from the group consisting of alkyl radicals containing 1 to 4 carbon atoms and alkoxy radicals containing 1 to 4 carbon atoms, the 2-imidazolin-2-ylamino group may be in any of the 5-, 6-, 7- or 8-positions of the quinoxaline nucleus, and R3, R4 and R5 each is located in one of the remaining 5-, 6-, 7- or 8-positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals containing 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as reduction in peripheral pain.
    • 治疗哺乳动物的方法包括向哺乳动物施用有效量以在哺乳动物中提供所需治疗效果,所述化合物选自具有下式的那些化合物:及其药学上可接受的酸加成盐及其混合物,其中R 1 并且R 2各自选自含有1至4个碳原子的烷基和含有1至4个碳原子的烷氧基,2-咪唑啉-2-基氨基可以在5-,6-,7- - 或8-位的喹喔啉核,R3,R4和R5各自位于喹喔啉核的剩余的5-,6-,7-或8-位之一,并且独立地选自Cl ,Br,H和含有1至3个碳原子的烷基。 当向哺乳动物施用时,这些化合物提供期望的治疗效果,例如减少外周疼痛。
    • 14. 发明授权
    • Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
    • 使用(2-咪唑啉-2-基氨基)喹喔啉衍生物的方法
    • US5373010A
    • 1994-12-13
    • US195184
    • 1994-02-10
    • Charles GluchowskiMichael E. GarstJames A. BurkeLarry A. Wheeler
    • Charles GluchowskiMichael E. GarstJames A. BurkeLarry A. Wheeler
    • A61K31/495C07D403/12A61K31/50
    • C07D403/12A61K31/495Y10S514/816Y10S514/854Y10S514/93
    • A method of treating a mammal comprises administering to a mammal an effective amount to provide a desired therapeutic effect in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## , pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R.sub.2 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R.sub.3 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7- or 8- positions of the quinoxaline nucleus; and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms. Such compounds, when administered to a mammal, provide desired therapeutic effects, such as constriction of one or more blood vessels and decongestion of one or more nasal passages.
    • 治疗哺乳动物的方法包括向哺乳动物施用有效量以在哺乳动物中提供选自下列化合物的化合物所需的治疗效果:具有下式的那些化合物:其药学上可接受的酸加成盐及其混合物 其中R 1和R 4独立地选自H和具有1至4个碳原子的烷基; R 2独立地选自H或具有1至4个碳原子的烷基,或者一起是氧代; R 3独立地选自H或具有1至4个碳原子的烷基,或者一起是氧代; 2-咪唑啉-2-基氨基可以在喹喔啉核的5-,6,7或8-位中的任一个中; 并且R5,R6和R7各自位于喹喔啉核的剩余的5-,6-,7-或8-位中的一个中,并且独立地选自Cl,Br,H和具有1至 3个碳原子。 当向哺乳动物施用时,这些化合物提供所需的治疗效果,例如一个或多个血管的收缩和一个或多个鼻通道的减充血。
    • 16. 发明授权
    • Methods for using (2-imidazolin-2-ylamino) quinoxaline derivatives
    • 使用(2-咪唑啉-2-基氨基)喹喔啉衍生物的方法
    • US5326763A
    • 1994-07-05
    • US10954
    • 1993-01-29
    • Charles GluchowskiMichael E. GarstJames A. BurkeLarry A. Wheeler
    • Charles GluchowskiMichael E. GarstJames A. BurkeLarry A. Wheeler
    • A61K31/495C07D403/12A61K31/50
    • C07D403/12A61K31/495Y10S514/816Y10S514/854Y10S514/93
    • A method of treating a mammal comprises administering to a mammal an effective amount to provide a reduction inflammation in the mammal of a compound selected from the group consisting of those having the formula: ##STR1## pharmaceutically acceptable acid addition salts thereof and mixtures thereof, wherein R.sub.1 and R.sub.4 are independently selected from the group consisting of H and alkyl radicals having 1 to 4 carbon atoms; the R.sub.2 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the R.sub.3 s are independently selected from H or alkyl radicals having 1 to 4 carbon atoms or are, together, oxo; the 2-imidazolin-2-ylamino group may be in any of the 5-, 6, 7- or 8- positions of the quinoxaline nucleus; and R.sub.5, R.sub.6 and R.sub.7 each is located in one of the remaining 5-, 6-, 7- or 8- positions of the quinoxaline nucleus and is independently selected from the group consisting of Cl, Br, H and alkyl radicals having 1 to 3 carbon atoms.
    • 治疗哺乳动物的方法包括向哺乳动物施用有效量以在哺乳动物中提供选自下列化合物的化合物的还原性炎症:具有下式的那些化合物:其药学上可接受的酸加成盐及其混合物,其中 R 1和R 4独立地选自H和具有1至4个碳原子的烷基; R 2独立地选自H或具有1至4个碳原子的烷基,或者一起是氧代; R 3独立地选自H或具有1至4个碳原子的烷基,或者一起是氧代; 2-咪唑啉-2-基氨基可以在喹喔啉核的5-,6,7或8-位中的任一个中; 并且R5,R6和R7各自位于喹喔啉核的剩余的5-,6-,7-或8-位中的一个中,并且独立地选自Cl,Br,H和具有1至 3个碳原子。